CCO Treatment Updates
Treatment Paradigms in Recurrent GBM: Today’s Options and Tomorrow’s Promising Directions
Virtual Presentations
Glioblastoma: Understanding the Challenge
|
Program Director: Patrick Y. Wen, MD
|
|
David Schiff, MD, provides a clinical overview of glioblastoma and reviews the genetic pathways involved in its pathogenesis, along with a discussion of MGMT methylation as a prognostic biomarker and tools for predicting survival in patients with glioblastoma.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the relevance of genetic factors in the pathophysiology, prognosis, and treatment of patients with GBM
- Discuss current and emerging prognostic approaches used to guide the treatment of GBM
- Describe factors implicated in the development of resistance to temozolomide in GBM patients
Abstract
|
Slideset: Glioblastoma: Understanding the Challenge
 |
|
David Schiff, MD, reviews the epidemiology, genetic factors, and prognostic biomarkers of glioblastoma.
Format: Microsoft PowerPoint (.ppt) |
File size: 860 KB
| Date posted: 11/25/2008
|
Current Treatment Options and Recommendations for Patients With GBM
|
Program Director: Patrick Y. Wen, MD
|
|
Tracy Batchelor, MD, MPH, reviews current treatment options and evidence-based recommendations for recurrent GBM.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the relevance of genetic factors in the pathophysiology, prognosis, and treatment of patients with GBM
- Discuss current standard approaches for the initial treatment of GBM including chemotherapy, surgery, and radiation
- Describe current data and clinical practice guidelines relevant to the treatment of patients with recurrent GBM
- Recount recent, ongoing, and planned investigations of regimens including targeted agents for patients with recurrent GBM
|
Slideset: Current Treatment Options and Recommendations for Patients with GBM
 |
|
Tracy Batchelor, MD, MPH, discusses current treatment standards for patients with glioblastoma.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.84 MB
| Date posted: 12/11/2008
|
Clinical Explorations With Targeted Agents in Recurrent GBM
|
Program Director: Patrick Y. Wen, MD
|
|
Timothy Cloughesy, MD, reviews targeted agents under investigation for the treatment of glioblastoma and discusses the issue of resistance when using these drugs in this setting.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Cite the biologic targets evaluated for GBM therapy
- Identify important factors that determine appropriate targets for therapy in GBM
- Explain the mechanisms of resistance that may arise as a consequence of targeted therapy in GBM
- Examine the issues associated with combination targeted therapy for GBM
|
Slideset: Clinical Explorations With Targeted Agents in Recurrent GBM
 |
|
Timothy Cloughesy, MD, discusses investigational targeted agents for recurrent glioblastoma.
Format: Microsoft PowerPoint (.ppt) |
File size: 6.46 MB
| Date posted: 12/1/2008
|
Audio Archive
Expert Insights: Issues in the Management of Glioblastoma
Patrick Y. Wen, MD discusses important issues in the management of patients with glioblastoma, including current treatment options, the role of biomarkers in selecting optimal treatment, and the future of targeted therapies.
|
 Audio File 16.5 MB
|
Disclaimer:
The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|